Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs. Beta blockers are well-established drugs widely used to treat cardiovascular conditions. Observational studies consistently report that beta blocker use in people with C...

Descripción completa

Detalles Bibliográficos
Autores principales: Cotton, Seonaidh, Devereux, Graham, Abbas, Hassan, Briggs, Andrew, Campbell, Karen, Chaudhuri, Rekha, Choudhury, Gourab, Dawson, Dana, De Soyza, Anthony, Fielding, Shona, Gompertz, Simon, Haughney, John, Lang, Chim C., Lee, Amanda J., MacLennan, Graeme, MacNee, William, McCormack, Kirsty, McMeekin, Nicola, Mills, Nicholas L., Morice, Alyn, Norrie, John, Petrie, Mark C., Price, David, Short, Philip, Vestbo, Jorgen, Walker, Paul, Wedzicha, Jadwiga, Wilson, Andrew, Lipworth, Brian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009490/
https://www.ncbi.nlm.nih.gov/pubmed/35422024
http://dx.doi.org/10.1186/s13063-022-06226-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009490/
https://www.ncbi.nlm.nih.gov/pubmed/35422024
http://dx.doi.org/10.1186/s13063-022-06226-8

Ejemplares similares